University of Pennsylvania School of Medicine May 8 2025 A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies. The new therapy diminished cancer in 81 percent of patients and resulted in complete remission in 52 percent, with some of the earliest patients treated experiencing durable remission for two years